Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.